Nurix Therapeutics Presents Promising BTK Degrader Data at ASH 2024
核心洞察
Nurix Therapeutics is presenting Phase 1a/b data on NX-5948, a BTK degrader, in relapsed/refractory CLL (搜索) patients at the ASH Annual Meeting.
NX-2127 and NX-5948 demonstrate facilitation of T cell functionality in chronic lymphocytic leukemia, according to Nurix Therapeutics' research.
Studies on BTK degradation as a therapeutic strategy for relapsed CNS lymphoma (搜索) will be showcased in a poster presentation by Nurix Therapeutics.
Nurix Therapeutics is presenting new clinical data from its Phase 1a/1b clinical trial of Bruton’s tyrosine kinase (搜索) (BTK) degrader program NX-5948 at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA. The data, to be presented in oral and poster sessions from December 7-10, 2024, highlight the potential of NX-5948 and NX-2127 in treating relapsed/refractory chronic lymphocytic leukemia (CLL (搜索)) and CNS lymphoma (搜索).
NX-5948 Shows Efficacy in Relapsed/Refractory CLL
Nirav N. Shah, M.D., M.S.H.P., Associate Professor of Medicine at the Medical College of Wisconsin, will present updated efficacy and safety results from the ongoing Phase 1a/b study of NX-5948 in patients with relapsed/refractory CLL (搜索). The oral presentation, titled "Efficacy and Safety of the Bruton’s Tyrosine Kinase (搜索) (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study," will take place on Monday, December 9, 2024, at 3:00 p.m. PT.
NX-5948 is an investigational, orally bioavailable, brain-penetrant small molecule degrader of BTK. It is designed to specifically eliminate BTK, a key growth signaling protein in B cells, through degradation by the ubiquitin proteasome system of the cell. The drug is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B-cell malignancies (搜索).
BTK Degraders Enhance T Cell Functionality in CLL
Another oral presentation will focus on the impact of NX-2127 and NX-5948 on T cell functionality in CLL (搜索). Tiana Huynh and colleagues will present data on how these cereblon-recruiting BTK degraders facilitate T cell functionality in chronic lymphocytic leukemia. This presentation is scheduled for Saturday, December 7, 2024, at 10:30 a.m. PT.
Novel Therapeutic Strategy for Relapsed CNS Lymphoma
Nurix will also present a poster on BTK degradation as a novel therapeutic strategy in relapsed CNS lymphoma (搜索). Jun Ma and team will showcase proof-of-concept studies in intracranial patient-derived, rodent models. The poster presentation is scheduled for Sunday, December 8, 2024, from 6:00 p.m. to 8:00 p.m. PT.
About Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative small molecules and antibody therapies. Their approach centers on modulating cellular protein levels as a novel treatment for cancer, inflammatory conditions, and other challenging diseases. Nurix's pipeline includes targeted protein degraders of Bruton’s tyrosine kinase (搜索) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B.